PHARMACEUTICAL COMPOSITIONS COMPRISING A THYROID HORMON AND THEIR THERAPEUTIC USE

• US 20110064773A1
• Filed: 05/16/2008
• Published: 03/17/2011
• Est. Priority Date: 05/16/2007
• Status: Abandoned Application

• Current Assignee: Centre National De La Recherche Scientifique, Inserm (institut national de la sant et de la recherche mdicale, Universite Joseph Fourier
• Original Assignee: Centre National De La Recherche Scientifique, Universite Joseph Fourier
• Inventors: Favier, Roland, Taleux, Nellie, Favier, Yann, Favier, Michelle, Favier, Boris, Leverve, Xavier
• Application Number:
  US12/600,154
• Publication Number:
  US 20110064773A1
• Time in Patent Office: Days
• US Class Current: 424/400
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/02 Nasal agents, e.g. decongestants
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/08 Antiseborrheics
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/14 of the thyroid hormones, e.g. T3, T4
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to a pharmaceutical composition comprising, as active substance, at least one hormone chosen among 3′,5′,3-triiodothyronine (rT3), a rT3 derived hormone, or a precursor of rT3, such as T4 in association with a molecule susceptible to promote the formation of rT3, in association with a pharmaceutically acceptable vehicle.

Claims

1-11. -11. (canceled)

12. A pharmaceutical composition comprising, as active substance, at least one hormone chosen among:

3′

,5′

,3-triiodothyronine (rT3),

a rT3 derived hormone, such as 3′

,3-diiodothyronine, 5′

,3-diiodothyronine, 3′

-iodothyronine, 5′

iodothyronine or 3-iodothyronine, or

a precursor of rT3, such as T4 in association with a molecule susceptible to promote the formation of rT3,

in association with a pharmaceutically acceptable vehicle.

13. The pharmaceutical composition according to claim 12, wherein said active substance is rT3.

14. The pharmaceutical composition according to claim 12, in a suitable form for the release of about 0.01 μ

g/kg/day to about 250 μ

g/kg/day, particularly about 0.01 μ

g/kg/day to about 25 μ

g/kg/day, particularly about 0.1 μ

g/kg/day to about 15 μ

g/kg/day of active substance, more particularly about 0.1 μ

g/kg/day to about 5 μ

g/kg/day of active substance, most particularly about 0.1 μ

g/kg/day to 1 μ

g/kg/day of active substance.

15. The pharmaceutical composition according to claim 12, comprising by dosage unit about 5 μ

g to about 1.5 g of active substance, particularly about 75 mg to about 750 mg of active substance.

19. The pharmaceutical composition according to claim 12, wherein said pharmaceutically acceptable vehicle refers to pharmaceutically acceptable solid or liquid, diluting or encapsulating, filling or carrying agents, which are usually employed in pharmaceutical industry for making pharmaceutical compositions.

20. The pharmaceutical composition according to claim 12, suitable for an administration via an oral, intravenous, intramuscular, subcutaneous, transcutaneous, nasal, intraperitoneal, sublingual, or rectal route.

21. The pharmaceutical composition according to claim 12, wherein said pharmaceutically acceptable vehicle allows a continuous, preferably constant, release, of said active substance.

23. The pharmaceutical composition according to claim 19, suitable for an administration via an oral, intravenous, intramuscular, subcutaneous, transcutaneous, nasal, intraperitoneal, sublingual, or rectal route.

24. The pharmaceutical composition according to claim 19, wherein said pharmaceutically acceptable vehicle allows a continuous, preferably constant, release, of said active substance.

16. A method for treating pathologies chosen among:

hyperglycemia, insulin resistance, beta pancreatic cell insufficiency, or related pathologies,

pathologies wherein the cholesterol and/or triglycerides plasma concentrations are higher than the normal concentrations, dyslipidemia, and

pathologies related to overweight or related to an excess of fat deposit,

comprising the administration in a patient in a need thereof of a pharmaceutical effective amount of one hormone chosen among;

3′

,5′

,3-triiodothyronine (rT3),

a rT3 derived hormone, such as 3′

,3-diiodothyronine, 5′

,3-diiodothyronine, 3′

-iodothyronine, 5′

iodothyronine, or 3-iodothyronine, and

a precursor of rT3, such as T4, in association with a molecule susceptible to promote the formation of rT3.

17. The method according to claim 16, for the treatment of pathologies chosen among:

diabetes, particularly type 1 or 2 diabetes,

beta pancreatic cell insufficiency, obesity,

overweight or related pathologies,

hypercholesterolemia, hypertriglyceridemia,

dyslipidemia,

alcoholic and non alcoholic hepatic steatosis,

atherosclerosis,

hepatopathies associated to a dysmetabolism,

cholecystopathies,

deposit of subcutaneous fat, particularly cellulite, and

vasomotor rhinitis.

18. The method according to claim 16, wherein said hormone is rT3.

22. A product comprising:

at least one hormone chosen among 3′

,5′

,3-triiodothyronine (rT3), a rT3 derived hormone, such as 3′

,3-diiodothyronine, 5′

,3-diiodothyronine, 3′

-iodothyronine, 5′

-iodothyronine, or 3-iodothyronine, or a rT3 precursor, such as T4 in association with a molecule susceptible to promote the formation of rT3,

at least one active substance activating the pancreatic secretion of insulin, particularly chosen among, or susceptible of slowing the digestive absorption of glucose,

as a combination product for a simultaneous, separate or sequential use intended for the treatment of diabetes.

22-1. A product comprising:

at least one hormone chosen among 3′

,5′

,3-triiodothyronine (rT3), a rT3 derived hormone, such as 3′

,3-diiodothyronine, 5′

,3-diiodothyronine, 3′

-iodothyronine, 5′

-iodothyronine, or 3-iodothyronine, or a rT3 precursor, such as T4 in association with a molecule susceptible to promote the formation of rT3,

at least one active substance activating the pancreatic secretion of insulin, particularly chosen among, or susceptible of slowing the digestive absorption of glucose,

as a combination product for a simultaneous, separate or sequential use intended for the treatment of diabetes.